Many soft-tissue sarcomas, which are rare types of cancers that form in fat, muscles and blood vessels, initially look like ordinary lumps. However, when a suspicious mass of this sort is removed without appropriate imaging, tissue diagnosis or oncological planning, the opportunity for the simplest and best-planned first operation may already have been lost.
Sarcomas in India, are therefore not only a problem of late diagnosis. Some are also operated on before a diagnosis is properly established. A first operation performed without sarcoma-specific planning can make subsequent treatment more extensive, even when the disease remains potentially curable.
A retrospective analysis in AIIMS, Delhi of 157 patients with localised extremity synovial sarcoma found that more than 70% of patients reached a specialist centre only after an unplanned surgery or a recurrence.
It may not look serious
Sarcomas are rare, accounting for about 1% of cancers in adults and roughly 15% of cancers in children. Their rarity is part of the challenge. Most soft-tissue lumps are benign, so neither patients nor clinicians naturally assume that a new lump is a cancer. Yet sarcoma can present with little more than a slowly enlarging swelling.
A soft-tissue sarcoma may appear well circumscribed, but that apparent boundary can be deceptive. Some tumours develop a surrounding pseudocapsule, and microscopic tumour cells may extend into or beyond it. If a sarcoma is removed without appropriate oncological margins, residual tumour may remain in the surgical bed. The operation that follows may then need to remove the previous scar and potentially contaminated tissues and, in some patients, may require more complex reconstruction.
Why unplanned removals are risky
The term ‘unplanned excision’ is used when a soft-tissue sarcoma is removed without appropriate preoperative imaging, histological confirmation or an oncological surgical plan. Evidence does not support the idea that such an operation automatically destroys the chance of cure. However, it can increase the risk of local recurrence and frequently creates the need for a second, wider operation to clear the tumour bed.
The AIIMS synovial sarcoma series illustrates both sides of this problem. Despite more than 70% of patients arriving after an unplanned operation or recurrence, limb salvage was still achieved in 64%. This is an important message for patients: an earlier inappropriate operation is serious, but it does not mean that amputation or treatment failure is inevitable. Prompt referral to a sarcoma team can still preserve meaningful treatment options.
Signs that should trigger a referral
Not every lump needs an MRI or a biopsy. But certain features should make a clinician stop before simply removing it. A soft-tissue mass that is enlarging, is about 5 centimetres or larger, lies deep to the fascia, has suspicious or indeterminate imaging features, or has returned after a previous removal deserves specialist assessment. Current imaging guidance recommends referral to a sarcoma or tumour reference centre before biopsy or surgery, when sarcoma is suspected.
For a suspicious extremity soft-tissue mass, MRI is usually the preferred local imaging test. If malignancy remains a concern, a carefully planned image-guided core-needle biopsy is generally the standard way to establish the diagnosis before definitive surgery. Small, superficial lesions may sometimes be managed differently, which is why the decision should be based on the whole clinical and imaging picture, rather than size alone.
Pain is not a reliable safety signal. Soft-tissue sarcoma can present as a painless lump, and the absence of pain should not reassure someone if a mass is enlarging or has other concerning features. The practical message is simple: a persistent or growing unexplained lump deserves an assessment, not an assumption.
Multi-disciplinary care
Sarcoma is not one disease but a heterogeneous family of cancers with many distinct subtypes. Diagnosis and treatment may require input from musculoskeletal radiology, specialist pathology, surgical oncology or orthopaedic oncology, radiation oncology and medical oncology. This is why major guidelines emphasise assessment in, or in close collaboration with, a specialist sarcoma centre when the diagnosis is suspected.
Image-guided core-needle biopsy has high diagnostic accuracy when it is properly planned and interpreted by experienced teams. The concern that a needle biopsy will routinely ‘spread’ a sarcoma is also misleading. Tumour seeding along a percutaneous biopsy tract is possible, but published data suggest that it is uncommon. The biopsy route should still be planned carefully because the tract may need to be considered during definitive surgery.
Dispelling harmful beliefs
Three beliefs are particularly harmful: that a painless lump must be harmless, that biopsy itself is more dangerous than obtaining a diagnosis, and that sarcoma automatically means amputation. None is a safe assumption. Modern sarcoma care is built around diagnosis before definitive treatment and, for extremity tumours, limb-preserving treatment is possible for many patients.
Better referral pathways between primary care, general surgical services and specialist centres can prevent avoidable unplanned excisions. The goal is not to send every small lump to a cancer centre; it is to recognise the few features that should trigger imaging, biopsy planning and specialist input before the first incision.
The first operation on a suspected sarcoma can shape what becomes necessary afterwards. For an unexplained lump with concerning features, diagnosis and planning should come before excision. Sometimes the most important cancer treatment decision is the one made before anyone enters the operating theatre.
(Dr. Siddharth Turkar is a consultant in medical oncology at Apollo Hospitals Navi Mumbai. drsiddharth_t@apollohospitals.com)
Published – August 21, 2026 10:10 am IST